The accurate measurement of mammographic density offers the potential to improve breast cancer risk prediction and to tailor screening protocols according to risk, according to a study published in Breast Cancer Research (16:439 doi:10.1186/s13058-014-0439-1). The article, “Digital mammographic density and breast cancer risk: a case-control study of six alternative density assessment methods,” demonstrates a strong connection between breast density and breast cancer risk.

Gamma Medica announced the company now offers Philips MicroDose SI, the first full-field digital mammography (FFDM) system that supports single-shot, non-invasive spectral imaging, as a complement to its market leading LumaGEM Molecular Breast Imaging (MBI) system. LumaGEM is a highly effective and cost-efficient technology for detecting breast cancer in patients with complex mammograms and dense breast tissue. The agreement with Philips will enable Gamma Medica to provide breast imaging suites with the option to purchase both technologies and offer the most advanced and safest commercially available dense breast solution for women. Philips will continue selling MicroDoseSI directly to customers.